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 Musculoskeletal health has a widespread impact on patients and the public health sector 
as a whole. Musculoskeletal pathology is ubiquitous, affecting one in two adult Americans. As a 
result, it is one of the largest contributors to patient and payer burden, with estimated direct costs 
of over $50B in 2019. Healthcare technology innovation has been growing rapidly over the 
years. The integration of these new technologies can provide vast benefits to patients, payers, 
and research for the future of the field. 
 The purpose of this paper is to explore the impact of technology integration in the field of 
musculoskeletal health and how this innovation will influence and advance the field’s delivery 
and treatment options in the years to come. This essay is supported through a literature review to 
examine the ideation of these integrations and progress to date along with interviews from 
industry experts and a program evaluation from an aspect of the author’s residency, Hospital for 
Special Surgery Innovation Institute. 
The development of musculoskeletal innovation revolutionizes clinical integration, 
medical device, care delivery, patient accessibility, and more. By improving outcomes, providing 
better quality care at lower cost, and better diagnostics and prevention, musculoskeletal 
innovation drives improved efficiencies for patients and providers. Digital healthcare is proving 
to be pivotal for the advancement of patient experience and empowerment throughout the care 
 
Technology in healthcare: Evaluating technological innovation in musculoskeletal care, 
advancement in delivery and treatment options 
 
Malena Gabrielle Hirsch, MHA, MBA 
 
University of Pittsburgh, 2021
 
 v 
continuum, also leading to improved clinical outcomes. For organizations in this space, best 
practices include emphasizing the impact on patients and on industry and highlighting the cross-
collaborative synergies between field experts.  
 vi 
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The ideation of this thesis stems from my internship experience at Hospital for Special 
Surgery supporting their Innovation Institute. Throughout my internship, I was exposed to 
proposals of new technological advancements and their potential impact on the field of 
musculoskeletal healthcare. In a specialty that affects so many patients worldwide, I found it 
inspiring that industries outside of traditional healthcare are finding ways to integrate and 
advance healthcare delivery and treatment options. This essay explores the development of 
technology into the field of musculoskeletal healthcare, how and where the future of 
technological integration may lead musculoskeletal care delivery and treatment, potential 
impacts on patients and payers, and finally, evaluating a program that focuses specifically on 
musculoskeletal innovation. 
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1.0  INTRODUCTION 
Musculoskeletal healthcare has a widespread impact on patients and the public health 
sector as a whole. Impacting over 130M patients in the U.S., musculoskeletal conditions are the 
second leading cause of global morbidity-related burden of disease and the cause of over 260M 
lost workdays per year in the U.S. (Musculoskeletal Key, 2017). In 2014, the annual average 
direct cost for patients with a direct musculoskeletal disease and for patients with a 
musculoskeletal disease in addition to other health issues combined was estimated to be up to a 
staggering $980.1B (Yelin et al., 2016). In 2019, musculoskeletal conditions accounted for one-
third of workers compensation cost, nearly 400K injuries per year, and an estimated $54B in 
direct costs—with indirect costs estimated to by five times the direct costs (Middlesworth, 2020). 
Efficient and innovative musculoskeletal healthcare delivery and treatment options are proving 
critical to the advancement of the field (WHO, 2019). Candidates to trailblaze this advancement 
are stemming from industries outside of traditional healthcare, such as digital-technology start 
ups and video game developers. More and more technology-enhanced companies are breaking 
into the foreground, as technological innovations are seeing benefits to improve healthcare-
related models of care. Further, companies are seeing an opportunity to leverage their 
technologies, motivating them to capture first dollars of new markets. 
As we shift to a more technologically advanced world, traditional models of care are 
becoming outdated. For generations, the healthcare industry has been battling between risk 
avoidance—as new innovations tend to be high risk—and “advancement aspiration,” i.e., 
investing in innovation to advance healthcare management, delivery, and research. 2020 health 
technology companies are at an all-time high in valuation, seeing valuations nearly twice as high 
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as 2019 and seeing “a combined market cap of $9.8B at IPO” (Reuter, 2021). These companies 
are competing in a fast-paced market to revolutionize how the healthcare industry views and 
utilizes technological integration. Research across the industry suggests that a failure to adopt 
technology transformation will prove to be fatal for healthcare organizations.  
Through an internship with Hospital for Special Surgery working with their Innovation 
Institute, the author was made aware of the vast opportunities that exist to merge technology with 
the field of musculoskeletal (MSK) healthcare. In the forefront of this advancement, the field of 
musculoskeletal health is collaborating with tools to advance treatment and care delivery options 
through the integrated use of machine learning, artificial intelligence (AI), robotics, medical 
devices, remote monitoring, and more. 
The aim of this essay is to examine the development and integration of technology in 
musculoskeletal healthcare delivery and treatment to date. The author will use literature review, 
interviews, and program evaluation to explore and evaluate how these integrations will influence 
and advance the field. Through this examination, the author will discuss integrative disruptors 
that may change the future of musculoskeletal healthcare delivery. 
1.1 MUSCULOSKELETAL CONDITIONS DEFINITION & IMPACT 
Musculoskeletal conditions encompass more than 150 diagnoses affecting the locomotor 
system, i.e., “muscles, bones, joints, and associated tissues such as tendons and ligaments” 
(WHO, 2021). Often characterized by persistent pain and “limitations in mobility, dexterity and 
functional ability,” musculoskeletal conditions significantly inhibit individuals’ quality of life. 
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These patients have a limited capability to work, to enjoy personal-social activities, and have 
been found to have associated impacts on mental health and wellbeing (WHO, 2021).  
Musculoskeletal conditions may be impermanent or chronic and affect patients from 
adolescence through elderly years. Contributors of musculoskeletal burden include low back 
pain, fractures, osteoarthritis, neck pain, amputations, rheumatoid arthritis, and other injuries 
(WHO, 2021). According to the 2017 Global Burden of Disease (GBD) study, musculoskeletal 
conditions accounted for 16% of all “years lived with disability” and were the highest contributor 
to global burden of disability. This study also found that between 20-33% of people globally live 
with the burden of a musculoskeletal condition; however, while there is evidence to prove 
significant burden of musculoskeletal conditions, there is widespread belief that the burden and 
pain is being underestimated globally (Blyth et al., 2019). 
Within the United States of America, more than 1 in 2 Americans over the age of 18 
reportedly live with a musculoskeletal condition, exceeding the combined number of Americans 
with cardiovascular or chronic respiratory conditions (Impact on Americans Exec Summary, 
Bone & Joint, 2016). In addition to the personal impact on patients, the social and economic 
implications of musculoskeletal conditions are staggering. Musculoskeletal disorders generated 
the highest healthcare-related expenditures in aggregate, exceeding $380B in 2016 (see Table 1) 
(Dieleman et al., 2020). 
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Table 1. Total Estimated Spending and Aggregated Health Categories for 2016.
 
Source: Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health 
Condition, 1996-2016. JAMA. 2020;323(9):863–884. doi:10.1001/jama.2020.0734. 
1.2 AUTHOR’S ROLE  
The author’s role for the purposes of this paper were that of 1) a student performing 
literature review and 2) a previous Business Intern at Hospital for Special Surgery. While at 
Hospital for Special Surgery, the author supported the Innovation Institute’s 2-person Care 
Delivery team. In this role, the author supported future virtual care offerings and potential 
partnerships with external companies. She completed preliminary research of potential partners, 
drafted discussion documents, and assisted with deal structure to support new collaborative 
partnerships. 
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2.0  BACKGROUND 
This section includes information to further explain technology development and 
advancement in the field of musculoskeletal healthcare, as well as the organization and its key 
functional department that was evaluated to better understand the topic discussed in this paper. 
2.1 DEVELOPMENT OF TECHNOLOGICAL INNOVATION IN HEALTHCARE 
AND MUSCULOSKELETAL HEALTH 
Broadly defined as “invention + adoption + diffusion,” healthcare innovation spans novel 
ideas, products, services, or care pathways (Kelly & Young, 2017). The incorporation of 
technology in these innovations, both from within and outside the medical field, further drives 
useable and desireable advances that enhance the benefits of current processes and standards. 
Technological innovation has been slowly integrating into healthcare over the past 50-60 years. 
Beginning with artificial pacemakers, magnetic resonance imaging (MRI) machines, and blood 
cell separators, technology in healthcare stemmed from clinical advancement in the ‘60s and 
‘70s. The development of the MRI in 1977 was an early and impactful technological integration 
into healthcare and was particularly valuable in the musculoskeletal field to allow physicians to 
distinguish between soft tissues in the body, aiding in musculoskeletal diagnostics.  
Fast forward 20 years, there were significant improvements to clinical uses of 
technology, with the da Vinci surgical system, digital hearing aids, and much more. In addition, 
the computerization of management systems and administration functions became a popular 
solution to reduce the profusion of identified medical errors (MDID, 2009).  
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Today, two more decades later in our current landscape, healthcare technology is almost 
vital to incorporate in various functions of the healthcare industry, including vast clinical 
integration, financial operations and performance improvement, technology-enabled patient 
engagement tools, digital care offerings, and digital transformation and interoperability. Other 
current advancements are looking at how to utilize artificial intelligence (AI), machine learning, 
and additional technology systems to aid in clinical decision making and consumer preference 
alignment. Specific to musculoskeletal healthcare, current innovations are aimed at improving 
patient outcomes while enabling greater cost-effectiveness. Some examples include AI-enabled 
medical devices, digital health apps aimed at MSK prevention, and biofeedback wearables for 
mobility monitoring and rehabilitation. 
In 2020, there were an estimated 3,000+ health tech startups, all aiming to transform the 
future of healthcare (Venture Scanner, 2020). Deloitte projects an annual growth rate of 5% to 
the healthcare market from 2019-2023 (Allen, 2020). This growth projection presents a 
signficiant opportunity to bring impact to the prevalent and costly specialty of musculoskeletal 
care. This paper will be exploring the technological integration specifically in musculoskeletal 
care delivery and treatment. 
2.2 HOSPITAL FOR SPECIAL SURGERY 
Hospital for Special Surgery (HSS) is a 205-bed specialty hospital focused on 
orthopedics, rheumatologic conditions, and overall musculoskeletal treatment. HSS has locations 
in New York, New Jersey, Connecticut, and Florida, and services patients from around the 
world. HSS has been ranked No. 1 for orthopedics for 11 consecutive years by U.S. News & 
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World Report (2010-2021) and was the Guardian of Excellence Award winner for the 7th 
consecutive year for outstanding patient experience. HSS is staffed by 389 active medical staff, 
280 advanced practice providers, over 100 training students, and over 4,900 staff members and 
performs more than 33,000 surgical procedures annually. Hospital for Special Surgery’s 
Innovation Institute has managed and supported a pipeline of technology & innovation projects 
since the 1970’s and continues to collaborate and support innovation in the field of 
musculoskeletal health today. 
2.3 KEY FUNCTIONAL DEPARTMENTS  
 INNOVATION INSTITUTE 
The HSS Innovation Institute was created to manage and enhance the pipeline of 
technology projects that HSS has been involved in since 1979. Focused entirely on advancing the 
field of musculoskeletal care, the Innovation Institute collaborates with physicians, researchers, 
surgeons, and scientists to improve clinical outcomes, enhance patient experience, and lower the 
cost of care delivery. The Innovation Institute supports internal and external advancements, 
particularly early-stage life sciences and care delivery innovations. 
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3.0  LITERATURE REVIEW 
The following section includes a compilation of studies and articles, organized by themes 
to better provide a framework for this essay.  
3.1 THE INTEGRATION AND PROGRESSION OF TECHNOLOGY IN 
MUSCULOSKELETAL HEALTHCARE 
 MEDICAL DEVICE 
The World Health Organization defines medical devices as any “instrument, apparatus, 
implement, machine, appliance, implant, reagent for in vitro use, software, material or other 
similar or related article, intended by the manufacturer to be used, alone or in combination, for 
human beings, for one or more of the specific medical purpose(s)” (n.d.). Medical devices are 
widely utilized for musculoskeletal healthcare diagnosis and treatment. New innovative 
technologies in the medical device field span from technological advancements to product 
innovation to the use of 3D printing and manufacturing and machine learning and AI. Many 
medical devices are being integrated with diagnostic data collection, machine learning, and 
artificial intelligence to enhance the efficiencies of musculoskeletal care. 
Diagnostics innovation has brought significant impact to musculoskeleltal conditions 
such as cerebral palsy. Gait analysis pairs motion analysis and video capture with physical exams 
to help accurately diagnose patients with cerebral palsy. Through the use of video capture on 
infrared cameras and motion analysis through surface electrode sensors, patient mobility can be 
tracked, recorded, and analyzed in 3D (CerebralPalsy.org, 2021). Analysis of bone and joint 
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motion is crucial for diagnosis as well, and traditional measuring included the use of anglers or 
de-adhesion markers on patients, which could cause poor accuracy and poor reproducibility. 
Healthcare technology companies have been developing measuring devices specific to 
musculoskeletal care that utilize image processing technology through 3D cameras and AI to 
analyze data (HealthcareDive, 2019). These diagnostic innovations help improve diagnostic 
accuracy and efficiency for musculoskeletal conditions. 
The development of medical device wearables has been monumental in the integration of 
the Internet of Things (IoT) and healthcare. Through the use of biosensors, machine learning, 
and analytics, wearables allow for diagnostic data collection, tracking, and assessment. 
Wearables have been highly regarded to giving patients the agency to advocate and better 
understand their health, in the comfort of their home. Research from 2020 is projecting that the 
Internet of Medical Things (IoMT) will balloon with a growth rate of 27.2% from 2020-2027 and 
projects that the market value will top $155.8B by 2027 (Acumen Research and Consulting, 
2020). With both patient impact and financial opportunity, many researchers expect to see more 
investment in the IoMT space, whether to wearables or other integrations. Regardless of how 
technology is incorporated in medical devices, there are many different pathways to innovate 
medical device in musculoskeletal care. 
 DIGITAL HEALTH APPLICATIONS 
Digital health adoption has been trending upward over the years, but recent public health 
events, specifically the COVID-19 global pandemic, have created an even larger surge of digital 
health adoption. Digital health spans categories such as “mobile health (mHealth), health 
information technology (IT), wearable devices, telehealth and telemedicine, and personalized 
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medicine” (FDA, 2020). Digital health applications utilize computing platforms, software, 
connectivity, and sensors to develop patient-facing platforms that range from general wellness to 
“companion” medical device applications, and more. 
There is a large opportunity for musculoskeletal-focused digital apps (MDAs) to evolve 
patient care through physical therapy and rehabilitation, pain management, and behavioral 
health. Digital health intervention can include patient-provider communication tools, health 
tracking, information services, and more. These digital health applications increase access to 
providers for patients who were previously unable to see their care provider regularly. The 
opportunity for this innovation is evident, as the market of global mobile health is expected to 
grow to over $110B by 2025 (Kwo, 2020). 
Digital health applications are being adopted by employers, payers, and individual 
entrepreneurial health-tech companies, with a majority focus on preventative care and injury 
reduction. Many of the applications aim to reduce the use of opioids and unnecessary surgery 
through encouraging physical therapy and other recovery treatments. These applications utilize 
different approaches to musculoskeletal-induced pain management, including treatment 
programs, mental health programs, and the use of complementary treatment such as using 
external sensors to monitor the affected area or hardware applications such as ECG to track 
movement. 
There is an abundant supply of health-related apps, with over 50,000 mobile health apps 
listed in the Apple App Store in Q4 of 2020 (Statista, 2021). With the upsurge in these apps, 
there are concerns that not all are created equal in terms of effectiveness and safety. In the MDA 
community, there is widespan recommendation that MDAs should be reviewed and cleared by 
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trained care providers and instructed to patients with ample education to correctly utilize the 
MDA. Further, when assessing MDAs, an evaluation should be conducted covering “usability, 
technical content, health content, security and transparency” (Kwo, 2020). Once appropriately 
vetted, digital health applications can provide patients with more autonomy for their care and 
more tools and resources to educate and support them throughout the musculoskeletal care 
continuum. 
 COMPUTER-AIDED NAVIGATION 
Computer-aided navigation and imaging analysis has become popular in the treatment of 
musculoskeletal conditions. Computer-aided navigation (CAN) during orthopedic surgery is the 
“use of computer-enabled tracking systems to facilitate alignment in a variety of surgical 
procedures, including fixation of fractures, ligament reconstruction, osteotomy, tumor resection, 
preparation of the bone for joint arthroplasty (knee and hip), and verification of intended implant 
placement” (UHC, 2021). CAN provides surgeons with technology-enabled support during 
procedures to assist with accuracy and efficiency. 
CAN integrates data acquisition, registration, and tracking with patient care. Data 
acquisition is incorporated through fluoroscopic, guided MRI, or imageless systems. Registration 
aides in matching the anatomical position of the field with the accompanying data, such as 
imaging or 3D anatomy. Data and accuracy tracking is integrated through the use of sensors and 
measurement devices that provide “feedback during surgery regarding the orientation and 
relative position of tools to bone anatomy.” CAN may be imaged-based or non-image-based, and 
the utilization of CAN during orthopedic procedures has been suggested to increase surgical 
accuracy, bone alignment, and reduce misplacement and malposition during surgery. Although 
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some form of computer-assisted navigation during orthopedic surgery has been implemented 
since the 1990’s, there is still active research to confirm if CAN surgeries deliver improved 
clinical outcomes and long-term improvement for musculoskeletal patients. Some studies 
suggest computer-aided navigation may lower revision rates, but this research is ongoing and the 
technology development remains active. 
3.2 IMPACT ON PATIENTS 
The impact that musculoskeletal innovation has on patients is extensive. By way of 
providing patients the tools and resources to gain education about their condition and treatment 
options, to improving accessibility, to hopeful clinical outcome improvement, healthcare 
technology bridges a gap that musculoskeletal patients face. 
 PATIENT EDUCATION AND EMPOWERMENT 
Due to integration of technological innovation in the healthcare field, patients are 
presented with more data-backed information about treatments and outcomes. This can empower 
patients to make more informed decisions about their care pathway. In a previous healthcare 
environment where patients had to solely rely on surgeons’ opinions, technological innovation 
enables precision medicine while supporting patient-centric care to account for patient 
preference and expectations (Bossi, 2021). 
Using virtual care models, patients can receive education to help better manage their 
conditions, track and assess their progress, and be guided in rehabilitation movements tailored to 
their specific musculoskeletal condition. These care offerings can be offered to patients at their 
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convenience and comfort, providing support to patients who previously may have had access 
issues. A study published in June 2020 showed that there is evidence supporting the efficacy of 
digital health interventions in reducing patient burden of musculoskeletal conditions, including 
improving pain, improving functional disability, and coping strategies (Hewitt et al., 2020). 
 IMPROVED ACCESS 
Healthcare innovation “looks to reduce cost, provide better treatment, and have more 
accessibility so more patients can have access to same high-quality care” (Bossi, 2021). 
Technological integration with healthcare improves patient accessibility through continuous care 
monitoring for more comprehensive diagnosis and treatment, digital health applications that can 
tailor unique patient needs, real-time access to care through telehealth offerings, and more. 
Providing patients with better access to care, particularly through mobile health platforms, 
further empowers patients to manage their own conditions. 
An example of improved access is patient utilization of virtual physical therapy solutions 
to improve symptoms from musculoskeletal disorders. Traditionally, there are limitations to the 
number of physical therapy sessions covered by insurance, and many times these covered 
sessions cease before the patient is fully recovered. New virtual care models can prolong patient 
access to care sessions and access to providers throughout the patients’ recovery (Olson, 2020). 
 CLINICAL OUTCOME IMPROVEMENT 
Technological integration in healthcare allows healthcare providers to collect and analyze 
more data than before, enabling forecasting models to determine more effective treatment 
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interventions. Integrating digital solutions into musculoskeletal models of care are widely 
thought to help close “innovation-adoption gaps” in the field, leading to improved clinical 
outcomes. 
As will be discussed in more depth later in this essay, technology has vastly improved 
research, testing, diagnostics, and treatment of gait abnormalities. The use of biofeedback 
markers and motion analysis have improved the diagnostic accuracy and capabilities of gait 
analyses. Different gait-analysis technologies are “constantly being refined to provide reliable 
measures of improvement from disease” (Lewis et al., 2019).  
Hinge Health, a leading musculoskeletal digital clinic startup, utilizes the combination of 
wearable sensors and remote delivery software to enable virtual physical therapy and behavioral 
health offerings for chronic musculoskeletal conditions. In 2017, Hinge Health had data from 
over 1,000 patients that “demonstrated a 55% improvement in both chronic low back pain and 
knee pain, while avoiding 60% of surgeries” (Hinge Health, 2017). The incorporation of 
technological advances and digital offerings presents significant improved outcomes for patients 
with musculoskeletal conditions. 
3.3 IMPACT ON PAYERS 
 COST OF MSK CONDITIONS TO PAYERS 
Musculoskeletal conditions are major drivers of expenses to health insurance payers. 
Costing payers over $260B in 2016, the impact of musculoskeletal conditions is significant. Low 
back and neck pain accounted for over $133B paid by private insurance, public insurance, and by 
individuals out-of-pocket. Other musculoskeletal disorders cost over $128B paid by the three 
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payer categories in 2016 (Dieleman et al., 2020). Musculoskeletal disorders including low back 
and neck pain, joint and limb pain, myalgia, and osteoporosis received majority of funding from 
private insurance (see Figure 1). Secondary to private insurance, public insurance funded over 
$90B to these disorders and out-of-pocket payments came in third, covering over $20B of 
funding for musculoskeletal disorders. 
A 2019 white paper by healthcare company Optum found that pharmaceutical expense is 
a significant contributor to musculoskeltal payer spending. Costing $130B in direct medical costs 
across all payers, musculoskeletal conditions did see a slight decrease in spending as care shifted 
to an outpatient model. However, the per-case spending is still increasing. Annual 
musucloskeletal per-case average spend was measured to grow by 15.4% in 2019. This growth 
rate, in addition to other projections for the rise in other musculoskeletal conditions, are expected 
to “contribute to a $73B increase in MSK spending by 2024” (Friedman, 2019). 
 
Figure 1. Estimated Health Care Spending by Payer and Type of Care in 2016. 
 
Source: Dieleman JL, Cao J, Chapin A, et al. US Health Care Spending by Payer and Health 
Condition, 1996-2016. JAMA. 2020;323(9):863–884. doi:10.1001/jama.2020.0734. 
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 REGULATORY IMPACT OF DIGITAL HEALTH OFFERINGS 
In the current age of the COVID-19 global pandemic, the government and healthcare 
payers have moved swiftly to change provisions and reimbursements for different virtual 
healthcare offerings. Centers for Medicare and Medicaid Services (CMS) relaxed regulations on 
telehealth services to ensure patients had access to care. Moving into a digital age has presented 
both challenges and opportunities for payers.  
Payers and providers have been adopting digital health applications and services over the 
past few years, as these technologies have proven to be beneficial and convenient for consumers. 
In 2011, a study found that private payers were relying on external health technology assessment 
(HTA) data in making coverage decisions for personalized medicine (Trosman et al., 2011). This 
newfound partnership that is developing between payers and providers, where payers can support 
covering digital health in exchange for payer benefits such as “initial capital investments, gain-
sharing arrangements, incentives for the payer’s members to participate, and fee structures for 
services offered” presents an interesting task for regulators (Friesdorf et al., 2019). Dr. Liz Kwo, 
MD, MBA, MPH from Harvard University found that FDA-approved medical applications are 
currently reimbursed by payers in varying amounts. Before the COVID-19 pandemic, 25% of 
integrated health networks were providing coverage for digital therapies and an additional 45% 
were interested in providing this coverage (Kwo, 2020). The continuous development of digital 
healthcare services and the partnerships between providers and payers to exchange data for 
coverage and reimbursement may complicate the landscape for regulators. When taking into 
consideration the “back end” negotiation that happens to reach reimbursement decisions, it is 
curious if regulators will create policies creating guidelines and rules around these partnerships. 
Technology in healthcare is presenting new considerations for regulators and it will be 
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interesting to see how the regulatory environment develops as healthcare technology and patient-
facing services become more commonplace. 
3.4 MARKET ANALYSIS 
This section includes a market analysis of various contributors that drive healthcare 
technology innovation. A report from Silicon Valley Bank found that healthcare technology 
companies raised a record $15B+ in funding in 2020 and surpassed biopharma in the number of 
deals for the first time (Reuter, 2021). Digital health companies in particular saw a surge in 2020, 
raising a total of over $3.7B in funding (Reuter, 2021). For the purposes of this essay, the main 
contributors specifically related to musculoskeletal health innovation include musculoskeletal 
health start-up organizations and medical device innovation. Medical device was chosen for the 
comparison of HSS medical device innovative work. Universities were included in this market 
analysis as these institutions have been making meaningful strides toward healthcare innovation. 
 MEDICAL DEVICE INNOVATION 
3.4.1.1 ZIMMER BIOMET 
 
Zimmer Biomet is a medical device manufacturer that was founded in 1927 and 
headquartered in Warsaw, Indiana. Zimmer Biomet focuses on innovative orthopedics and has 
developed and integrated the use of digital health offerings across diagnostics, surgical 
intervention, biologics, sports medicine, and various musculoskeletal subspecialties. Innovation 
is a core value of Zimmer Biomet, even sponsoring a Connected Health Innovation Award in 
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2018, which was open to any digital health start-up interested in improving outcomes and lower 
costs in musculoskeletal health (Zimmer Biomet, 2021). 
3.4.1.2 DEPUY SYNTHES | J&J MEDICAL DEVICES 
 
DePuy Synthes is a medical device solution company within the Johnson & Johnson 
Medical Devices group. Founded in 1895 and headquarted in Raynham, Massachusetts, DePuy 
specializes in joint reconstruction, trauma, craniomaxillofacial, spinal surgery, and sports 
medicine. With focuses in orthopedics and spine innovations, DePuy utilizes robotic-assisted 
clinical solutions, material innovation through the use of 3D bioprinting, digital surgery 
integration, and more (DePuy, 2021). 
3.4.1.3 MEDTRONIC 
Medtronic is a medical device company that holds a strong emphasis on innovation. 
Founded in 1949 in Minneapolis, Minnesota, the company has a number of product inventions in 
the spinal and orthopedic space and use technology innovation such as algorithms and AI, 
biosensors, augmented reality, and material science. The Medtronic Innovation Lab combines 
human-centered design and technology to create innovations geared to alleviate pain, restore 
health, and extend life. Medtronic also encourages invention submissions to be evaluated by 
Medtronic for potential partnership through their Meaningful Innovation vertical. Medtronic’s 
innovation team has been recognized with a handful of awards honoring tech insights and 
innovation leader impact (Medtronic, 2021). 
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 MSK HEALTH TECH START UPS 
3.4.2.1 HINGE HEALTH 
 
Hinge Health is a healthcare technology startup founded in 2015 that offers a digital 
solution to treat chronic musculoskeletal conditions. Hinge Health focuses on the continuum of 
musculoskeletal care, from prevention through to post-surgery. The digital platform offers virtual 
sessions with physical therapists and clinicians, one-on-one health coaching, and sensor 
technology that provides feedback and tracking to patients in real-time. Hinge conducted the 
world’s largest digital MSK cohort study to support their digital solution’s benefits outcomes 
(Hinge Health, 2021). 
3.4.2.2 SPARTA SCIENCE 
Sparta Science Force Plate Machine Learning (FPML) utilizes machine learning and 
predictive analytics through force plate data to emphasize musculoskeletal health. Founded in 
2007, Sparta Science uses collected data to identify patient movements and provide training 
plans based on patient need. Utilized in healthcare and rehabilitation, professional and collegiate 
sports, and the military, Sparta’s FPML helps treat preexisting conditions, reduce future injuries, 
and optimize performance. Results from Sparta analyses are integrated with a user platform to 
track performance and movements and to receive recommended exercises to holistically improve 
musculoskeletal health (Sparta Science, 2021). 
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 UNIVERSITIES 
Universities play a significant role in research and development that contributes to new 
innovation. With the Bayh-Dole Act signed into law in 1980, academic institutions gained the 
rights to the titles and licensing revenue that resulted from university research (NIH, n.d.). This 
Act fundamentally changed the extent that universities contributed to and benefitted from 
innovations, and stimulated innovation in the life sciences sector. Universities specialize in 
technology transfer (also called “tech transfer”), which includes research and inventions that are 
transformative to daily life. Further, it is the commercialization of these innovations created by 
institutions (AUTM, n.d.). In 2015, U.S. academic institutions accounted for 5.5% of all U.S. 
investment in the medical and health research sector, investing nearly $9B (Ezell, 2019).  
In 2018, over 17K new technology transfer patent applications were completed and over 
7,500 tech transfer patents were issued (Nag et al., 2020). This figure rose over 250% from 
patents issued in 2008 (National Science Board, 2018). Over $70B was spent on federally 
sponsored research at U.S. universities in 2018, generating almost $3B in licensing revenue (Nag 
et al., 2020). Universities are expected to continue research and innovation in the healthcare 
sector. Educational institutions have a plethora of healthcare data and medical knowledge, and 
the advancement of AI and computing power that universities hold will enable research and 
development in this meaningful and lucrative industry (Nag et al., 2020). 
3.5 BARRIERS 
Barriers regarding the adoption of technology by health systems and other healthcare-
related organizations span across organizational culture, capital spending, and lack of necessary 
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personnel. A significant barrier may include the capital required to continuously invest in 
innovative healthcare technology. Economists estimate that 40-50% of annual healthcare cost 
increases are related technological advances to expand medical capabilities (Baker et al., 2008). 
To illustrate, diagnostic imaging, which is frequently used in musculoskeletal healthcare, often 
presents initial cost efficiencies; however, “improvements in quality and rapid growth in the use 
of these techniques … led to higher total spending on diagnostic services” (Baker et al., 2008). 
Further, the advancements in diagnostic capabilities led patients to utilize more healthcare 
services than before, indirectly increasing spending. 
Authors from the healthcare journal Health Affairs found that novel innovations with low 
productivity are an excessive cost driver, and that “novel procedures tend to incompletely replace 
traditional procedures,” leaving expense from inefficient utilization of new and old procedures 
(Cahan et al., 2020). Despite these considerations, many studies and sources strongly suggest 
that healthcare technology enables sustainable, cost-effective care.  
New healthcare innovations can pose significant risk to developers and providers. Large 
moves into an unknown territory can be quite intimidating for healthcare organizations. 
However, these risks are proving to be necessary for providers to stay competitive and current in 
today’s healthcare climate. Risk averse organizations may be slower to adopt these technologies, 
which may result in a competitive, operational, and efficiency lag. As an example, early adopters 
of MRI machines in the 1980s found competitive advantage through factors such as more 
accurate diagnostics leading to increased demand and revenue. While there was cost and risk 
associated with adopting this technology initially, the early adopting healthcare providers saw 
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roughly five years of competitive gain before the market became concentrated (Bhidé et al., 
2019). 
Lack of expertise and understanding needed of the “complex ecosystem and interactions 
that underpin healthcare” when leveraging digital technologies can be futile to a successful 
implementation and serve as a barrier as well (Chehade et al., 2020). Along with a lack of needed 
expertise, companies that cannot effectively direct the necessary change management and culture 
realignment that a shift toward innovation requires may find themselves at a cross with their 
organization. Another barrier related to organizational culture includes a health system which 
maintains a siloed outlook, where transformation can be hindered due to the lack of cross-
collaboration. This perspective may lead to a failed adoption of new technological innovations 
geared to improve patient outcomes and achieve greater cost-effectiveness, potentially limiting a 
health system’s capacity for fully integrative medicine and will limit the patient continuum of 
care (Bansal, 2018). 
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4.0  PROGRAM EVALUATION: HSS INNOVATION INSTITUTE 
This section will discuss the organization that the author got significant first-hand 
exposure to over the course of a summer internship June 2020 – September 2020. Through 
working with a musculoskeletal innovation institute directly, the author was able to gain a deeper 
understanding of how innovations are approached, developed, and operationalized. 
4.1 TEAM AND CHARGE 
The Hospital for Special Surgery Innovation Institute is focused on developing the 
innovative landscape of musculoskeletal care to improve clinical outcomes, patient experience, 
and cost of care delivery. Through a commitment to being a leader in the industry, HSS 
Innovation Institute aims to be at the forefront of new innovations that will change the 
musculoskeletal industry as a whole.  
The HSS Innovation Institute team has 11 different professionals with backgrounds 
ranging from life sciences, medicine, and engineering to business development and intellectual 
property management. The Innovation Institute is comprised of three focus areas: care delivery, 
life sciences, and medical devices. Through collaboration and commercialization of novel 
concepts and inventions, the Innovation Institute develops, markets, and licenses innovative 
technologies to enable the use of these technologies to patients who could benefit from them. 
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4.2 INNOVATIONS FROM HSS 
HSS engages in collaborative partnerships with industry, investors, and entrepreneurs to 
commercialize a portfolio of technologies and co-develop new offerings in musculoskeletal care. 
HSS shares its expertise, know-how, and network of resources when developing these new 
ventures and care models/offerings. This section highlights some of the innovations that the HSS 
Innovation Institute is working to bring to market or has already brought to market in 
collaboration with its partners. 
 HSS AND ZIMMER BIOMET: mymobility® with Apple Watch® Remote Care 
Management System 
HSS collaborated with Zimmer Biomet to enhace their patient-facing digital platform. 
Zimmer Biomet’s Mymobility platform in conjunction with Apple Watch facilitates 
communication between patients and their clinicians/care teams throughout their surgical 
journey. This platform “acts as a virtual care team member by providing patients with support 
and guidance at the direction of their healthcare professional as they prepare for and recover 
from orthopedic procedures from the comfort of their home.” Through this partnership, 
healthcare systems and clinicians nationwide will be able to access HSS Orthopedic Care 
Pathways through the mymobility platform, commercially available in 2021. 
 HSS AND SCIENTIFIC ANALYTICS INC.: DARI Motion Platform 
HSS and Scientific Analytics Inc. (SAI) collaborated on a care delivery technology that 
uses computer vision technology to measure human movement patterns. SAI uses its proprietary, 
FDA-cleared, markerless motion capture technology to analyze and inform movement quality, 
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including generating clinical insights. The DARI Motion platform was validated through HSS 
beta testing at the HSS Motion Analysis Lab, and is integrated with HSS by the use of HSS 
knowledge and know-how (see Appendix A). 
 HSS AND MATHYS EUROPEAN ORTHOPEDICS: BalanSysTM UNI 
HSS surgeons and Mathys Medical LTD collaborated to develop the BalanSysTM UNI 
medical device, which was “designed to recreate normal kinematics of the knee joint while 
reducing stresses in the polyethylene insert.” Aimed to be utilized on singular condyle arthritis 
patients, indicated treatment may suggest unicondylar knee replacement. Unicondylar implants 
uncover the affected section while keeping the healthy cavity intact. The use of mobile-bearing 
technology allows “an ultra-high molecular weight polyethylene insert to articulate with both the 
femoral and tibial components” (HSS Innovation Porfolio, 2020). This collaboration reduces 
stresses and wear on the replacement due to its large contact areas at femoral and tibial 
interfaces. 
4.3 INTERVIEWS  
The purposes of these interviews was to better understand best practices and challenges 
that innovators in this space may be experiencing. The interviews were also an opportunity for 
the student to learn how success was measured in different innovative environments. All 
interviews were conducted within one month of each other to ensure that the information 
collected would reflect the interviewees’ current views of the organization and industry as a 
whole. Interviewees were chosen from the key functional area, HSS Innovation Institute. The 
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main themes for each interview were the interviewees’ perceptions about the development of 
technological integration in musculoskeletal care, impact of innovation to the musculoskeletal 
industry at large, best practices, challenges, and measuring success. Interviewees were informed 
that the interview was being conducted for academic purposes, related to the author’s project. 
Below are key themes and points drawn from the interviews.  
 
 DEVELOPMENT OF INNOVATION IN MSK HEALTHCARE 
When speaking with leaders in musculoskeletal innovation at Hospital for Special 
Surgery, there was consensus that development in this medical specialty will realize significant 
benefits to patients; however that it is still lagging comparatively. From innovations to new 
implants to new care pathways for patients, “innovation has always existed, just at different rates 
and speeds. We are now in an era where innovations are more transformative to the industry and 
empowering to patients” (Bossi, 2021). Further, the Chief Innovation Officer and Senior Vice 
President of Innovation and Development at HSS added that given the burden of these 
conditions, “musculoskeletal innovations have the opportunity to be highly impactful, as there 
has been little dedication to innovate in this space compared to other disease categories” (Achan, 
2021). The Director of Innovation and Technology Commercialization concluded that a 
contributor to the rate of this innovation is that “industry partnerships have grown significantly 
over the past few years to drive innovation in this field, specifically in the care delivery and 
digital space” (Vijayan, 2021).  
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 IMPACT OF INNOVATION ON MSK HEALTHCARE 
Innovation in this space is having an impact on the industry at large as it relates to 
musculoskeletal healthcare. Regarding the advancement of treatment options, Associate Director 
of Care Delivery, Sandra Bossi, remarked that “innovations are permitting the collection and 
analysis of more data than before, enabling us to build forecasting models to determine efficacy 
of different treatment options” (Bossi, 2021). These predictive and prescriptive models can 
impact treatment options by providing more data-backed decision making that will educate care 
providers in making the best decision for the patient. Impact to the industry comes in the form of 
bringing value to payers. “In leveraging and using innovative technologies, high-quality 
outcomes and value-based conversations can be achieved” (Achan, 2021). Another impact 
identified in the interviews was that of research and development brought on by academic 
innovation. Following the Bayh-Dole Act, “university innovation has been accelerated. Tech 
transfer is presenting vast opportunities and innovations that will further the advancement of 
musculoskeletal condition treatment” (Vijayan, 2021).  
 BEST PRACTICES 
When it comes to the success that HSS has found, the intervewiees all shared the 
sentiments of highlighting the impact and the importance of the people. Leonard Achan 
remarked how emphasizing organizational mission and the impact to patients is necessary to 
drive advancement to the industry as a whole. Further, he stressed the need to strive for adding 
knowledge and value to the industry and to patients, as opposed to focusing on the profits. This 
sentiment is humbling and emulates the genuineness of Hospital for Special Surgery, as there is 
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lucrative opportunity in this space but the focal point for the Hospital is on the impact they can 
bring to patients and to the industry as a whole.  
 Beyond the altrutic motivation for innovating, the interviewees also stressed the 
importance of identifying the right stakeholders and achieving buy-in. Against organizational 
and cultural barriers, buy-in from all necessary perspectives is crucial to push an innovation to 
fruition. Stakeholders can come from medical, technology, and entrepreneurial fields and all 
must emphasize building synergies. Sandra Bossi also stressed that expertise in one field alone 
will never be sufficient: “It is crucial to emphasize cross-functional collaboration, to find true 
believers in the innovation, and to be thoughtful about when to present/implement a new idea for 
it to be a success” (Bossi, 2021). All of these factors, in tandem, enable successful innovation 
from ideation to industry. 
 CHALLENGES TO ORGANIZATIONS WANTING TO INNOVATE 
The interviewees also discussed challenges that both HSS and other organizations face 
when striving to be a leader in musculoskeletal innovation. These challenges span across 
organizational culture, the market and competitive space, and regulatory barriers. Cultural issues 
include but are not limited to: organizational complacency, resistance to change, organizational 
misalignment, and discouraged workforce due to failed attempts. When talking with Sandra 
Bossi, she stressed the importance of timing when presenting new innovation development, as 
rejection rates can be high in the innovative landscape with “likely only one to two projects out 
of ten being successful” (Bossi, 2021). Teams that face this rejection may lose motivation, so the 
leaders of innovation must be persistant to counterbalance this challenge of burnout. The 
interviewees also reflected on the overall market, and many commented on the ballooning of 
29 
innovation over the years, saturating the competitive landscape in an already high-risk setting. 
Another significant consideration is the extensive regulatory, legal, and compliance barriers, 
including the need for a large budget for legal work. Through the influx of these external 
partnerships, the HSS legal team is inundated, which can slow the timeline and process to initiate 
the collaboration. Further, there are many rules around how patient data can be utilized, 
inhibiting certain advancement. Sandra Bossi specifically remarked on the lack of a national 
database, which inhibits development of certain algorithms and models. The complex regulatory 
environment requires a team that is dedicated to navigating this space in pursuit of bringing 
improved innovations to patients and to the industry. 
 DEFINING SUCCESS 
Success is measured in a variety of ways depending on the perspective of medical 
innovation. In my interviews, I gained three different perspectives of how success is measured in 
the environment of musculoskeletal technological innovation. These perspectives are not 
inclusive of all potential measurements of success for this complex field. 
When speaking to the Chief Innovation Officer at HSS, it was communicated that their 
success is measured by the “mission, charge, community, and move into the market” (Achan, 
2021). There are more tangible measurements of success such as sales and inventions; however, 
as an industry leader, HSS values measuring success through accountability and accessibility, 
ensuring new innovations can reach various communities. 
Tech transfer innovations measure success using a variety of metrics. An inexhaustive list 
of these metrics include invention disclosures, filed patent applications, patent issuances, number 
of licenses, patent cost reimbursement, revenues, or number of startup organizations coming 
30 
from your institution. Due to the nature of tech transfer innovations, these metrics of success 
have more standardization to measure across competitors. 
When it comes to care delivery, success is often measured on providing better value: 
lowering cost and offering more accessible and higher quality care (Bossi, 2021). Other metrics 
to measure success may include scaling HSS standards of care nationwide through collaborative 
partnerships, often with technology driven companies that HSS may have an equity stake in. This 
feeds into other metrics such as how successful the partnerships are and the commercialization 
success of these inventions/partnerships. 
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5.0  DISCUSSION  
Healthcare innovation is coming from many different perspectives and can be applied to 
various aspects of musculoskeletal treatment, delivery, and care models. Ranging from 
organizations that emphasize medical device innovation or digital health intervention to ones that 
are open to all kinds of innovation that may impact musculoskeletal care, the market is growing 
both in competition and in merit. Through innovative technological integrations, healthcare 
technology is helping revolutionize the way patients get access to care and the quality of that 
care.  
There has been a long history of the integration of technology into healthcare over the 
past 50 years. Beginning with devices to aid in diagnostics and clinical interventions, we are 
currently seeing the versatility in healthcare technology through digital health applications, 
wearables, use of artificial intelligence, and much more. There’s no telling where health-tech 
innovation may be in another 50 years. 
It is important to note that some research was not entirely convinced of the clinical 
outcome benefits that musculoskeletal technology suggests (Cahan et al., 2020). Although 
musculoskeletal technologies have been on the rise over the years, clinical outcomes should be 
measured carefully when technologies have been utilized. This will aid in giving a fuller picture 
to the benefits these technologies provide, although often at a considerable cost. 
The Innovation Institute at Hospital for Special Surgery emphasized best practices in the 
commitment to innovate, in stressing adding value to both the industry and to patients over 
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financial incentive, in encouraging cross-collaboration, and in engaging all necessary 
stakeholders and attaining buy-in for ultimate success.  
The collaboration and trust required on many parties dedicated to innovating care and 
treatment of musculoskeletal conditions is obvious. It is through hard work, commitment to 
growth, and a drive to innovate that HSS and other organizations like it are able to invest in 
pursuing novelties that may change the future of musculoskeletal care forever. Musculoskeletal 
health has a widespread impact on public health, affecting roughly 1 in 2 adult Americans. 
Considering the pace that healthcare innovation is moving, new technologies that are geared to 
prevent and treat chronic musculoskeletal conditions bring substantial impact to patients. 
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6.0  CONCLUSION  
The chase for innovation in musculoskeletal care remains tenacious, as there are many 
different applications of healthcare technology in this specialty. There are different subsets of 
technologies to be integrated with the treatment of musculoskeletal conditions; these subgroups 
appear to self-categorize into prevention-focused, which often include digital platforms, and 
intervention-focused, including medical device and computer-aided navigation. Regardless of the 
integration, the aim resides to make musculoskeletal care more efficient, accurate, and cost-
effective. 
Musculoskeletal conditions continue to be a driver in patient burden of disease and in 
cost to the U.S.’s annual healthcare spend and payer burden. Focusing on ways to improve the 
efficiencies of treating these conditions, which impacts so many and costs the U.S. so much, may 
help bring widespread value to the industry. When looking to the future, there is an excitement 
and hunger amongst those innovative companies who internalize this effort.   
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